<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546789</url>
  </required_header>
  <id_info>
    <org_study_id>MS200527_0059</org_study_id>
    <secondary_id>2020-001920-32</secondary_id>
    <nct_id>NCT04546789</nct_id>
  </id_info>
  <brief_title>Effect of Hepatic Impairment on M2951 (BTK Inhibitor) PK</brief_title>
  <official_title>Phase I Open-label, Single Dose Study to Investigate the Effect of Hepatic Impairment on the PK of Evobrutinib (M2951)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the pharmacokinetic (PK) and safety of M2951 (Bruton's tyrosine&#xD;
      kinase [BTK] inhibitor) in participants with different degrees of hepatic impairment compared&#xD;
      to participants with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Actual">May 16, 2021</completion_date>
  <primary_completion_date type="Actual">May 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Day 1 up to Day 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Laboratory Parameters and Electrocardiogram Findings</measure>
    <time_frame>Day 1 up to Day 6</time_frame>
    <description>Number of participants with clinically significant change from baseline in vital signs, laboratory parameters and electrocardiogram findings will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Plasma Concentration (Tmax) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Elimination Half Life (t1/2) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-Time Curve From Time Zero to Time 12 Hours After M2951 (BTK inhibitor) Administration (AUC0-12)</measure>
    <time_frame>Pre-dose up to 12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Time 24 Hours After M2951(BTK inhibitor) Administration (AUC0-24)</measure>
    <time_frame>Pre-dose up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Total Body Clearance (CL/f) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution During Terminal Phase (VZ/f) of M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of Unbound Drug (M2951 [BTK inhibitor]) in the Plasma (fu)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Plasma Concentration for Unbound Drug (M2951 [BTK inhibitor]) From Time Zero to Infinity (AUC0-inf-u)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration of Unbound M2951 (BTK inhibitor) (Cmax, u)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Oral Clearance (CL,u/F) of Unbound M2951 (BTK inhibitor)</measure>
    <time_frame>Pre-dose up to 32 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1: Normal Hepatic Function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy participants who have normal hepatic function with sex, age (± 10 years; &gt;= 18 years old and =&lt; 79 years old), and weight (± 10 percent; &gt;= 50 kilogram (kg) and =&lt; 120 kg) matching with the mild and moderate hepatic impairment cohorts will receive single oral dose of M2951 (BTK inhibitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Mild Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment based on Child-Pugh Class A score of 5 or 6 will receive single oral dose of M2951 (BTK inhibitor).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Moderate Hepatic Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment based on Child-Pugh Class B score of 7 to 9 will receive single oral dose of M2951 (BTK inhibitor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2951 (BTK inhibitor)</intervention_name>
    <description>Participants will receive a single oral dose of M2951 (BTK inhibitor).</description>
    <arm_group_label>Group 1: Normal Hepatic Function</arm_group_label>
    <arm_group_label>Group 2: Mild Hepatic Impairment</arm_group_label>
    <arm_group_label>Group 3: Moderate Hepatic Impairment</arm_group_label>
    <other_name>Evobrutinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with normal hepatic function only will be overtly healthy as determined&#xD;
             by medical evaluation, including no clinically significant abnormality identified on&#xD;
             physical examination or laboratory evaluation and no active clinically significant&#xD;
             disorder, condition, infection or disease that would pose a risk to participant safety&#xD;
             or interfere with the study evaluation, procedures, or completion OR&#xD;
&#xD;
          -  Participants with moderately impaired hepatic function only will be considered to have&#xD;
             moderately (Child-Pugh class B and confirmed liver cirrhosis) impaired hepatic&#xD;
             function and has been clinically stable for at least 1 month prior to Screening OR&#xD;
&#xD;
          -  Participants with mildly impaired hepatic function only will be considered to have&#xD;
             mildly (Child-Pugh class A and confirmed liver cirrhosis) impaired hepatic function&#xD;
             and has been clinically stable for at least 1 month prior to Screening&#xD;
&#xD;
          -  Have a body weight within 50.0 and 120.0 kilogram (kg) and body mass index (BMI)&#xD;
             within the range 19.0 and 36.0 kilogram per square meter (kg/m^2)&#xD;
&#xD;
          -  Female participants are not pregnant or breastfeeding, and at least one of the&#xD;
             following conditions applies&#xD;
&#xD;
          -  Not a woman of childbearing potential (WOCBP)&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical history of autoimmune disorder with hepatic influence (Hashimoto thyroiditis&#xD;
             and rheumatic diseases allowed)&#xD;
&#xD;
          -  History of any malignancy&#xD;
&#xD;
          -  Diseases and surgeries of the gastrointestinal tract, which could influence the&#xD;
             gastrointestinal anatomy and mobility. Prior history of cholecystectomy or&#xD;
             inflammatory bowel disease, and any clinically relevant surgery within 6 months prior&#xD;
             to Screening&#xD;
&#xD;
          -  History of chronic or recurrent acute infection or any bacterial, viral, parasitic or&#xD;
             fungal infections within 30 days prior to Screening and at any time between Screening&#xD;
             and admission, or hospitalization due to infection within 6 months prior to Screening&#xD;
&#xD;
          -  History of shingles within 12 months prior to Screening&#xD;
&#xD;
          -  History of drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity&#xD;
             to the active drug substance and/or formulation ingredients; history of serious&#xD;
             allergic reactions leading to hospitalization or any other hypersensitivity reaction&#xD;
             in general, which may affect the safety of the participant and/or outcome of the trial&#xD;
             per the Investigator's discretion&#xD;
&#xD;
          -  Participants with impaired hepatic function will be excluded who had Primary and&#xD;
             secondary biliary cirrhosis.&#xD;
&#xD;
          -  Participants with impaired hepatic function will be excluded with Clinical evidence of&#xD;
             severe ascites.&#xD;
&#xD;
          -  Participants with impaired hepatic function will be excluded with Hepatic&#xD;
             encephalopathy Grade greater than 1&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200527_0059</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.merckgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

